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Abstract
The daily number of outdoor spores was counted and the cases
of community-acquired invasive aspergillosis (IA) were observed
over a period of 31 months. The outdoor fungal load preceding
IA occurrences was signiﬁcantly higher than that measured dur-
ing IA-free periods, underlining the importance of preventive
measures to protect high-risk patients, even at home.
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Airborne fungi are natural components of the ecosystem,
and are commonly found in outdoor and indoor environ-
ments. Exposure to some species, such as Aspergillus fumiga-
tus, is associated with major opportunistic invasive fungal
infections, an important cause of morbidity and mortality in
patients with profound neutropenia or in those who are
severely immunosuppressed [1]. The nosocomial acquisition
of invasive aspergillosis (IA) has been convincingly demon-
strated in both epidemic situations (e.g. during construction
and renovation work) and non-epidemic settings [2,3]. In
non-epidemic situations, the air concentration of Aspergillus
sp. and other fungi in a haematology unit was correlated with
the incidence of IA [3]. During hospitalization, severely
immunocompromised patients at high risk for IA are usually
cared for in high-efﬁciency particulate air-ﬁltered rooms sup-
plied with laminar airﬂow and positive air pressure [4,5].
Maintaining good air quality within the hospitals substantially
contributes to reducing the incidence of hospital-acquired
Aspergillus infections [6]. However, numerous sporadic cases
of IA or other invasive ﬁlamentous fungal infections are
acquired outside the hospital setting [1,7,8]. It is noteworthy
that the inﬂuence of the outdoor ﬁlamentous fungal (FF)
ﬂora on the occurrence of community-acquired IA (or non-
hospital-acquired IA) has very recently attracted interest [9].
The aim of our work was ﬁrst to prospectively study the
outdoor daily fungal spore concentrations and the IA cases
over a 31-month period [10], and to compare the outdoor
FF spore load measured during two periods: a period before
community-acquired IA was diagnosed (with three scenarios:
10, 20 and 30 days before diagnosis), and a period with no
community-acquired IA diagnosed in our teaching Hospital.
Moreover, this comparison was also performed with the
inclusion of both hospital-acquired IA cases and cases of
undetermined origin.
The outdoor fungal spores were sampled daily with a
Burkard 7-day volumetric trap (Burkard Manufacturing,
Rickmansworth, UK) situated near the hospital. Fungal
spores were trapped on a melinex adhesive tape, and their
daily concentrations were measured with an optical micro-
scope [10,11]. Each month, the Aspergillosis Committee of
our teaching hospital reviewed and classiﬁed IA cases as pro-
ven, probable, or possible, using the European Organization
for Research and Treatment of Cancer criteria for diagnosis
[12]. Cases of IA were considered to be community-acquired
if symptoms attributable to IA were already present on
admission [7]. For dating of infection, the onset of the ﬁrst
symptoms was used whenever it was known. If precise dat-
ing of the onset of symptoms was not possible, the date of
the ﬁrst diagnostic criteria was used. Among community-
acquired IA cases, only patients living <20 km from the hos-
pital were assessed, as this distance encompasses the town
and suburban area. Furthermore, according to criteria previ-
ously described, hospital-acquired IA cases were deﬁned by
suggestive symptoms beginning more than 10 days after the
patient’s admission. IA cases were classiﬁed as being of unde-
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termined origin if clinical symptoms appeared during the ﬁrst
10 days of hospitalization or if the Aspergillosis Committee
was unable to determine when the symptoms began [7].
Data were summarized in terms of medians and percentiles
(25–75), and Mann–Whitney tests were applied because of
asymmetrical distribution.
Altogether, 43 cases of IA were diagnosed during this 31-
month study period, including seven cases of nosocomial IA
acquired in our hospital, 22 cases of community-acquired IA,
and 12 cases of IA undetermined origin (Table 1). However,
among the 22 patients with community-acquired IA, only 12
lived in the geographical area considered (town and suburb).
Among these 12 cases, IA was probable in ten cases and
possible in two cases. The onset of symptoms was precisely
known in nine cases; in the other three, the date of the ﬁrst
diagnostic criteria recorded corresponded to either the
admission day (n = 2) or the following day (n = 1). Brieﬂy,
the clinical data of the 12 patients were as follows: six of
them were treated for haematological diseases; three agranu-
locytosis patients had acute myeloid leukaemia (initial diagno-
sis for one, induction chemotherapy for the second, and
condition regimen for the third); one agranulocytosis patient
received chemotherapy for non-Hodgkin lymphoma; one
patient had received an allogeneic stem cell transplant for
myeloma 9 months previously; and the last patient received
chemotherapy associated with corticotherapy for chronic
lymphoid leukaemia. Moreover, three patients received che-
motherapy associated with corticosteroids for pancreatic
cancer, lung adenocarcinoma, and oropharyngeal cancer, two
received long-term corticosteroid therapy for idiopathic
pulmonary ﬁbrosis and for chronic respiratory deﬁciency,
and one patient had AIDS (CD4 <10/mm3).
Furthermore, among the 12 patients with IA of undeter-
mined origin, only ﬁve lived in the geographical area consid-
ered; there were two proven cases, two probable cases, and
one possible IA. During our 31-month study, seven cases of
nosocomial IA acquired in Grenoble’s hospital were diag-
nosed: one proven case, four probable cases, and two possi-
ble cases. All of these seven patients were hospitalized in the
same adult haematology ward (WB). This ward was equipped
with only partial air control (85% central opacimetric ﬁltra-
tion). The patients with agranulocytosis could come and go
freely from their rooms with a mask, visits were not limited,
and room doors were not systematically shut [10].
The median value (interquartile range) of the daily count
of fungal spores during the 943-day-long study were
139 spores/day (33–567 spores/day). The daily fungal spore
load ﬂuctuation, the 12 cases of community-acquired IA, the
seven cases of nosocomial IA and the ﬁve cases of under-
mined origin are shown in Fig. 1. Furthermore, at the end of
our 31-month study, we retrospectively compared the medi-
ans of the daily fungal spore counts of the 10 days preceding
the date of symptom onset of community-acquired IA in
each of the 12 patients (95 days) with those of the remaining
days (corresponding to 848 days). As the incubation period
of this infectious disease is not known, two other periods
TABLE 1. Number and annual incidence rate of invasive aspergillosis (IA) diagnosed in hospital
No. of hospitalization
daysa
No. of nosocomial
IAs
No. of IAs of
undetermined origin
No. of community-
acquired IAs
Total no.
of IAs
31 months 1 552 232 7 12 (5b) 22 (12c) 41 (+2d)
Mean/year 600 864 2.71 4.64 8.51 (4.65) 16.64
Incidence rate per
100 000 patient-days
– 0.45 – – –
aNumber of hospitalization days in the whole hospital.
bAmong the 12 patients with IA of undetermined origin, ﬁve lived <20 km from Grenoble Teaching Hospital (the city and the suburb).
cAmong the 22 patients with community-acquired IA, 12 lived in the city and the suburbs.
dTwo nosocomial cases diagnosed in our hospital were acquired in another hospital.
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FIG. 1. Daily fungal spores and invasive
aspergillosis (IA). Twelve community-
acquired IA cases (ten probable and two
possible), ﬁve IAs of undetermined ori-
gin (two proven, two probable, and one
possible) and seven nosocomial IA cases
(one proven, four probable, and two
possible) were considered.
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were also analysed, 20 days (175 days) and 30 days
(251 days) before the occurrence of community-acquired
IA—and compared with the complementary periods, 768
and 692 days, respectively. The medians of the fungal load in
the 95, 175 and 251 days corresponding to the periods of
10, 20 and 30 days prior to occurrence of IA were 303, 250
and 217 spores/day, as compared with 124, 124 and
123 spores/day for the complementary periods (Table 2). It
was shown that the fungal load was signiﬁcantly higher during
the periods before the occurrence of community-acquired
IA than during the periods when no case of IA was recorded
(IA-free periods) (p £0.001, p £0.01 and p £0.01 for the
periods of 10, 20 and 30 days prior to IA, respectively). The
same analysis performed with the hospital-acquired cases
plus the cases of undetermined origin showed that the
occurrence of these 12 cases was also preceded by a high
outdoor FF load (Table 2).
The maintenance of good air quality in the critical areas
of a hospital is effective in preventing and reducing the
acquisition of mould infections within the hospital [5,6].
Now, the environmental risk of nosocomial aspergillosis is
better known and controlled, although the respective pro-
portions of aspergillosis acquired in hospital and aspergillo-
sis revealed during hospitalization (in cases of previously
non-diagnosed colonization) are still debated [13,14]. As
some of the patients at risk for IA are either discharged
from the hospital or ambulatory-treated, the cases of com-
munity-acquired IA are proportionally more numerous than
those of hospital-acquired IA (49% vs. 18%, respectively), as
shown in our epidemiological surveillance of IA between
2000 and 2002 [7]. In this study, we found that the out-
door FF spore load was higher before the occurrence of
community-acquired IA than during the periods without
infections, and could potentially favour Aspergillus exposure
of immunocompromised patients at high risk for IA. Fungal
species other than Asperillus, although most of them are
non-pathogenic, can serve as good indirect markers of a
higher risk of invasive nosocomial aspergillosis [3]. More-
over, although no reasonable threshold of conidial concen-
tration above which the risk of IA increases has been given
in the literature, most authors recommend Aspergillus air
counts of <0.1–1 CFU/m3 in protective isolation suites [6].
In outdoor environments, the FF load is considerably
higher. Consequently, we can assume that an increase in
airborne fungal spores raises the probability of them being
inhaled by a susceptible host. Recently, Panackal et al. [9]
showed that the person-month IA rate was positively asso-
ciated with environmental spore counts in Seattle, USA,
although the precise origins of acquisition of IA were not
determined in their study. Thus, as we previously showed
that the number of outdoor airborne spores contributed to
an increase of FF ﬂora in the conventional haematology
wards in our hospital, an analysis of the outdoor FF spore
load during the period before the seven hospital-acquired
cases and the ﬁve cases of undetermined origin vs. the
period without IA was performed [10]. As expected, a high
TABLE 2. Comparison of outdoor fungal spore levels during periods preceding the cases of community-acquired invasive
aspergillosis (IA) (a) and preceding the nosocomial IAs plus the cases of undetermined origin (b) vs. the respective IA-free
periods
Outdoor fungal spores
Total period of 943 days
)10 daysa )20 daysb )30 daysc
No. Median No. Median No. Median
(a) Community-acquired IA (n = 12)
Period before IA 139 (33.25–567.25) 95 303 (73.5–711.75) 175 250 (53.25–665) 251 217.5 [53–675]
IA-free period 848 124 (31–549.5) 768 124 (28.5–534.5) 692 123 (28–517.75)
p* £0.001 £0.01 £0.01
(b) Nosocomial IA + IA of undetermined origin (n = 12)
Period before IA 139 (33.25–567.25) 106 239.5 (62–820) 146 261 (73–762) 179 259 (75–680.25)
IA-free period 837 133 (32–540) 797 123 (30–529) 764 117.5 (28.5–543)
p* £0.05 £0.001 £0.001
Medians of number of spores/day and range (25–75) are reported.
The medians of outdoor spores measured 10 daysa, 20 daysb and 30 daysc before the 12 cases of IA were analysed and compared with the medians of spores measured dur-
ing the periods obtained without considering those days (IA-free periods). For example, the median of the set of 10 days before the occurrence of community-acquired IA
(95 days) was compared with the median of spores during the IA-free periods (943)95 days).
No.: Number of days before or without the 10, 20 or 30 days preceding the 12 cases of community-acquired IA or the 12 cases of nosocomial IA (n = 7) plus the cases of
undetermined origin (n = 5).
*p by Mann–Whitney test.
CMI Research Note 1389
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1387–1390
outdoor load was observed before these 12 cases,
emphasizing, as recommended by numerous authors, the
importance of high-efﬁciency particulate air ﬁltration and
laminar airﬂow in high-risk units [4,6].
Our observation also underlines the importance of pre-
ventive measures outside the hospital. In our study, seven
IA cases were nosocomial, corresponding to an incidence
rate of 0.45 cases/100 000 patient-days, but the number of
community-acquired cases (22 cases) was higher. Further-
more, some IAs of undetermined origin could potentially
also be acquired at home. Therefore, we believe that the
implementation of prevention strategies in environments
other than hospitals would be beneﬁcial in reducing the
incidence of these infections. As air control measures in a
patient’s residence are difﬁcult to implement, the use of
simple and widely available measures, such as facemasks
and avoidance of dusty and humid places, is the best alter-
native [15]. Patients at high risk should also avoid activities
such as gardening, mowing, handling fresh ﬂowers, and vac-
uuming [16]. Moreover, antifungal prophylaxis with posaco-
nazole can be recommended for some patients at high risk
for IA [17]. However, such pharmacological prophylaxis
cannot be proposed to all patients at risk for invasive
mould infections: on the one hand, it is expensive, and on
the other, some patients are immunosuppressed for several
years, often with a lower incidence of IA than in the
patient group in which posaconazole is currently recom-
mended.
Therefore, it is currently difﬁcult to envisage treatment
for such a long period. Furthermore, it seems likely that, in
the future, the incidence of community-acquired invasive
mould infections will rise, as a certain number of high-risk
patients spend more time outside the hospital setting.
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